Show simple item record

Meaning and purpose in Huntington’s disease: a longitudinal study of its impact on quality of life

dc.contributor.authorSokol, Leonard L.
dc.contributor.authorTroost, Jonathan P.
dc.contributor.authorKluger, Benzi M.
dc.contributor.authorApplebaum, Allison J.
dc.contributor.authorPaulsen, Jane S.
dc.contributor.authorBega, Danny
dc.contributor.authorFrank, Samuel
dc.contributor.authorHauser, Joshua M.
dc.contributor.authorBoileau, Nicholas R.
dc.contributor.authorDepp, Colin A.
dc.contributor.authorCella, David
dc.contributor.authorCarlozzi, Noelle E.
dc.date.accessioned2021-09-08T14:37:04Z
dc.date.available2022-09-08 10:37:03en
dc.date.available2021-09-08T14:37:04Z
dc.date.issued2021-08
dc.identifier.citationSokol, Leonard L.; Troost, Jonathan P.; Kluger, Benzi M.; Applebaum, Allison J.; Paulsen, Jane S.; Bega, Danny; Frank, Samuel; Hauser, Joshua M.; Boileau, Nicholas R.; Depp, Colin A.; Cella, David; Carlozzi, Noelle E. (2021). "Meaning and purpose in Huntington’s disease: a longitudinal study of its impact on quality of life." Annals of Clinical and Translational Neurology (8): 1668-1679.
dc.identifier.issn2328-9503
dc.identifier.issn2328-9503
dc.identifier.urihttps://hdl.handle.net/2027.42/169327
dc.description.abstractObjectivePrevious work in Huntington’s disease (HD) has shown that a sense of meaning and purpose (M&P) is positively associated with positive affect and well‐being (PAW); however, it was unknown whether HD‐validated patient‐reported outcomes (PROs) influence this association and how M&P impacts PROs in the future. Our study was designed to examine if HD‐validated PROs moderate the relationship between M&P and PAW and to evaluate if baseline M&P predicts 12‐ and 24‐month changes in HD‐validated PROs.MethodsThis was a longitudinal, multicenter study to develop several PROs (e.g., specific for the physical, emotional, cognitive, and social domains) for people with HD (HDQLIFE). The sample consisted of 322 people with HD (n = 50 prodromal, n = 171 early‐stage manifest, and n = 101 late‐stage manifest HD). A single, multivariate linear mixed‐effects model was performed with PAW as the outcome predicted by main effects for M&P and several moderators (i.e., an HD‐validated PRO) and interactions between M&P and a given PRO. Linear‐mixed models were also used to assess if baseline M&P predicted HD‐validated PROs at 12 and 24 months.ResultsHigher M&P was positively associated with higher PAW regardless of the magnitude of symptom burden, as represented by HD‐validated PROs, and independent of disease stage. In our primary analysis, baseline M&P predicted increased PAW and decreased depression, anxiety, anger, emotional/behavioral disruptions, and cognitive decline at 12 and 24 months across all disease stages.InterpretationThese findings parallel those seen in the oncology population and have implications for adapting and developing psychotherapeutic and palliative HD interventions.
dc.publisherWiley Periodicals, Inc.
dc.titleMeaning and purpose in Huntington’s disease: a longitudinal study of its impact on quality of life
dc.typeArticle
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelNeurology and Neurosciences
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/169327/1/acn351424_am.pdf
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/169327/2/acn351424.pdf
dc.identifier.doi10.1002/acn3.51424
dc.identifier.sourceAnnals of Clinical and Translational Neurology
dc.identifier.citedreferenceCarlozzi NE, Downing NR, Schilling SG, et al. The development of a new computer adaptive test to evaluate chorea in Huntington disease: HDQLIFE Chorea. Qual Life Res 2016; 25: 2429 – 2439.
dc.identifier.citedreferenceCarlozzi NE, Boileau NR, Paulsen JS, et al. End‐of‐life measures in Huntington disease: HDQLIFE meaning and purpose, concern with death and dying, and end of life planning. J Neurol 2019; 266: 2406 – 2422. https://doi.org/10.1007/s00415‐019‐09417‐7
dc.identifier.citedreferenceCella D, Nowinski C, Peterman A, et al. The neurology quality‐of‐life measurement initiative. Arch Phys Med Rehabil 2011; 92: S28 – S36. https://doi.org/10.1016/j.apmr.2011.01.025
dc.identifier.citedreferenceCarlozzi NE, Goodnight S, Kratz AL, et al. Validation of Neuro‐QoL and PROMIS mental health patient reported outcome measures in persons with Huntington disease. J Huntingtons Dis 2019; 8: 467 – 482.
dc.identifier.citedreferenceCarlozzi NE, Boileau NR, Roché MW, et al. Responsiveness to change over time and test‐retest reliability of the PROMIS and Neuro‐QoL mental health measures in persons with Huntington disease (HD). Qual Life Res 2020; 29: 3419 – 3439. https://doi.org/10.1007/s11136‐020‐02596‐1
dc.identifier.citedreferencePilkonis PA, Choi SW, Reise SP, et al. Item banks for measuring emotional distress from the Patient‐Reported Outcomes Measurement Information System (PROMIS®): depression, anxiety, and anger. Assessment 2011; 18: 263 – 283. https://doi.org/10.1177/1073191111411667
dc.identifier.citedreferenceCella D, Yount S, Rothrock N, et al. The Patient‐Reported Outcomes Measurement Information System (PROMIS). Med Care 2007; 45: S3 – S11. https://doi.org/10.1097/01.mlr.0000258615.42478.55
dc.identifier.citedreferenceCella D, Riley W, Stone A, et al. The patient‐reported outcomes measurement information system (PROMIS) developed and tested its first wave of adult self‐reported health outcome item banks: 2005–2008. J Clin Epidemiol. 2010; 63: 1179 – 1194. https://doi.org/10.1016/j.jclinepi.2010.04.011
dc.identifier.citedreferenceCarlozzi NE, Boileau NR, Chou KL, et al. HDQLIFE and neuro‐QoL physical function measures: responsiveness in persons with huntington’s disease. Mov Disord 2020; 35: 326 – 336.
dc.identifier.citedreferenceCarlozzi NE, Ready RE, Frank S, et al. Patient‐reported outcomes in Huntington’s disease: quality of life in neurological disorders (Neuro‐QoL) and Huntington’s disease health‐related quality of life (HDQLIFE) physical function measures. Mov Disord 2017; 32: 1096 – 1102. https://doi.org/10.1002/mds.27046
dc.identifier.citedreferenceCarlozzi NE, Schilling SG, Lai J‐S, et al. HDQLIFE: the development of two new computer adaptive tests for use in Huntington disease, Speech Difficulties, and Swallowing Difficulties. Qual Life Res 2016; 25: 2417 – 2427.
dc.identifier.citedreferenceCarlozzi NE, Hahn EA, Frank SA, et al. A new measure for end of life planning, preparation, and preferences in Huntington disease: HDQLIFE end of life planning. J Neurol 2018; 265: 98 – 107. https://doi.org/10.1007/s00415‐017‐8677‐7
dc.identifier.citedreferenceCarlozzi NE, Boileau NR, Paulsen JS, et al. Psychometric properties and responsiveness of Neuro‐QoL Cognitive Function in persons with Huntington disease (HD). Qual Life Res 2020; 29: 1393 – 1403. https://doi.org/10.1007/s11136‐019‐02391‐7
dc.identifier.citedreferenceLai JS, Goodnight S, Downing NR, et al. Evaluating cognition in individuals with Huntington disease: Neuro‐QoL cognitive functioning measures. Qual Life Res 2018; 27: 811 – 822. https://doi.org/10.1007/s11136‐017‐1755‐6
dc.identifier.citedreferenceGershon RC, Rothrock N, Hanrahan R, et al. The use of PROMIS and assessment center to deliver patient‐reported outcome measures in clinical research. J Appl Meas 2010; 14: 304 – 314. https://doi.org/10.1002/mds.27908
dc.identifier.citedreferenceBenjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Ser B. 1995; 57: 289 – 300.
dc.identifier.citedreferenceRoberts BW, Luo J, Briley DA, et al. A systematic review of personality trait change through intervention. Psychol Bull 2017; 143: 117 – 141. https://doi.org/10.1037/bul0000088
dc.identifier.citedreferenceBoyle PA, Buchman AS, Barnes LL, Bennett DA. Effect of a purpose in life on risk of incident Alzheimer disease and mild cognitive impairment in community‐dwelling older persons. Arch Gen Psychiatry 2010; 67: 304 – 310.
dc.identifier.citedreferenceJulayanont P, McFarland NR, Heilman KM. Mild cognitive impairment and dementia in motor manifest Huntington’s disease: classification and prevalence. J Neurol Sci 2020; 408: 116523.
dc.identifier.citedreferenceSudore RL, Lum HD, You JJ, et al. Defining advance care planning for adults: a consensus definition from a multidisciplinary Delphi panel. J Pain Symptom Manage 2017; 53: 821 – 832.e1. https://doi.org/10.1016/j.jpainsymman.2016.12.331
dc.identifier.citedreferenceDowning NR, Goodnight S, Chae S, et al. Factors associated with end‐of‐life planning in Huntington disease. Am J Hosp Palliat Care 2018; 28: 440 – 447. https://doi.org/10.1177/1049909117708195
dc.identifier.citedreferenceKing LA, Hicks JA, Krull JL, Del Gaiso AK. Positive affect and the experience of meaning in life. J Pers Soc Psychol 2006; 90: 179 – 196.
dc.identifier.citedreferenceHicks JA, King LA. Meaning in life and seeing the big picture: positive affect and global focus. Cogn Emot 2007; 21: 1577 – 1584.
dc.identifier.citedreferenceSalsman JM, Schalet BD, Park CL, et al. Assessing meaning & purpose in life: development and validation of an item bank and short forms for the NIH PROMIS®. Qual Life Res 2020; 29: 2299 – 2310. https://doi.org/10.1007/s11136‐020‐02489‐3
dc.identifier.citedreferenceKachian ZR, Cohen‐Zimerman S, Bega D, et al. Suicidal ideation and behavior in Huntington’s disease: systematic review and recommendations. J Affect Disord 2019; 250: 319 – 329. https://doi.org/10.1016/j.jad.2019.03.043
dc.identifier.citedreferenceVan Orden KA, Witte TK, Cukrowicz KC, et al. The Interpersonal theory of suicide. Psychol Rev 2010; 117: 575 – 600.
dc.identifier.citedreferenceHeisel MJ, Flett GL. Does recognition of meaning in life confer resiliency to suicide ideation among community‐residing older adults? A Longitudinal Investigation. Am J Geriatr Psychiatry 2016; 24: 455 – 466. https://doi.org/10.1016/j.jagp.2015.08.007
dc.identifier.citedreferenceZarotti N, Dale M, Eccles F, Simpson J. Psychological interventions for people with Huntington’s disease: a call to arms. J Huntingtons Dis 2020; 9: 231 – 243.
dc.identifier.citedreferenceWalker FO. Huntington’s disease. Lancet 2007; 369: 218 – 228.
dc.identifier.citedreferenceFrank S. Treatment of Huntington’s disease. Neurotherapeutics 2014; 11: 153 – 160.
dc.identifier.citedreferenceKilloran A, Biglan KM. Current therapeutic options for Huntington’s disease: good clinical practice versus evidence‐based approaches? Mov Disord 2014; 29: 1404 – 1413.
dc.identifier.citedreferenceRodrigues FB, Abreu D, Damásio J, et al. Survival, mortality, causes and places of death in a European Huntington’s disease prospective cohort. Mov Disord Clin Pract 2017; 4: 737 – 742. Available from http://www.ncbi.nlm.nih.gov/pubmed/30363513
dc.identifier.citedreferenceVictorson D, Carlozzi NE, Frank S, et al. Identifying motor, emotional‐behavioral, and cognitive deficits that comprise the triad of HD Symptoms from patient, caregiver, and provider perspectives. Tremor Other Hyperkinet Mov 2014; 4: 224. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24757585
dc.identifier.citedreferenceCarlozzi NE, Schilling SG, Lai J‐S, et al. HDQLIFE: development and assessment of health‐related quality of life in Huntington disease (HD). Qual Life Res 2016; 13: 2441 – 2455. https://doi.org/10.1007/s11136‐016‐1386‐3
dc.identifier.citedreferenceHo AK, Gilbert AS, Mason SL, et al. Health‐related quality of life in Huntington’s disease: which factors matter most? Mov Disord 2009; 15: 574 – 578. https://doi.org/10.1002/mds.22412
dc.identifier.citedreferenceHo A, Hocaoglu M. Impact of Huntington’s across the entire disease spectrum: the phases and stages of disease from the patient perspective. Clin Genet 2011; 80: 235 – 239.
dc.identifier.citedreferenceDawson S, Kristjanson LJ, Toye CM, Flett P. Living with Huntington’s disease: need for supportive care. Nurs Health Sci 2004; 6: 123 – 130. Available from http://www.ncbi.nlm.nih.gov/pubmed/15130098
dc.identifier.citedreferenceCarlozzi NE, Downing NR, McCormack MK, et al. New measures to capture end of life concerns in Huntington disease: meaning and purpose and concern with death and dying from HDQLIFE (a patient‐reported outcomes measurement system). Qual Life Res 2016; 8: 2403 – 2415. Available from http://www.ncbi.nlm.nih.gov/pubmed/27393121
dc.identifier.citedreferenceErlangsen A, Stenager E, Conwell Y, et al. Association between neurological disorders and death by suicide in Denmark. JAMA 2020; 4: 444 – 454. Available from https://jamanetwork.com/journals/jama/fullarticle/2760389
dc.identifier.citedreferenceSokol LL, Lum HD, Creutzfeldt CJ, et al. Meaning and dignity therapies for psychoneurology in neuropalliative care: a vision for the future. J Palliat Med 2020; 23: 1155 – 1156. Available from http://www.ncbi.nlm.nih.gov/pubmed/32877285
dc.identifier.citedreferenceJohnson MO, Frank S, Mendlik M, Casarett D. Utilization of hospice services in a population of patients with Huntington’s disease. J Pain Symptom Manage 2018; 55: 440 – 443. https://doi.org/10.1016/j.jpainsymman.2017.09.004
dc.identifier.citedreferenceKleiman EM, Beaver JK. A meaningful life is worth living: meaning in life as a suicide resiliency factor. Psychiatry Res 2013; 210: 934 – 939.
dc.identifier.citedreferenceHeisel MJ, Flett GL. Purpose in life, satisfaction with life, and suicide ideation in a clinical sample. J Psychopathol Behav Assess 2004; 26: 127 – 135.
dc.identifier.citedreferenceEdwards MJ, Holden RR. Coping, meaning in life, and suicidal manifestations: examining gender differences. J Clin Psychol 2001; 57: 1517 – 1534.
dc.identifier.citedreferenceMeier DE, Emmons CA, Wallenstein S, et al. A national survey of physician‐assisted suicide and euthanasia in the United States. N Engl J Med 1998; 23: 1193 – 1201. https://doi.org/10.1056/NEJM199804233381706
dc.identifier.citedreferenceChochinov HM, Wilson KG, Enns M, Lander S. Depression, hopelessness, and suicidal ideation in the terminally Ill. Psychosomatics 1998; 39: 366 – 370. https://doi.org/10.1016/S0033‐3182(98)71325‐8
dc.identifier.citedreferenceMcClain CS, Rosenfeld B, Breitbart W. Effect of spiritual well‐being on end‐of‐life despair in terminally‐ill cancer patients. Lancet 2003; 361: 1603 – 1607.
dc.identifier.citedreferenceRosenfeld B, Cham H, Pessin H, Breitbart W. Why is Meaning‐Centered Group Psychotherapy (MCGP) effective? Enhanced sense of meaning as the mechanism of change for advanced cancer patients. Psychooncology 2018; 27: 654 – 660. https://doi.org/10.1002/pon.4578
dc.identifier.citedreferenceRosenfeld B, Breitbart W, Galietta M, et al. The schedule of attitudes toward hastened death: measuring desire for death in terminally III cancer patients. Cancer 2000; 88: 2868 – 2875.
dc.identifier.citedreferenceBreitbart W, Rosenfeld B, Gibson C, et al. Impact of treatment for depression on desire for hastened death in patients with advanced AIDS. Psychosomatics 2010; 51: 98 – 105. https://doi.org/10.1016/S0033‐3182(10)70669‐1
dc.identifier.citedreferenceBreitbart W, Rosenfeld B, Pessin H, et al. Depression, hopelessness, and desire for hastened death in terminally ill patients with cancer. JAMA 2000; 13: 2907 – 2911. https://doi.org/10.1001/jama.284.22.2907
dc.identifier.citedreferenceBreitbart W, Heller KS. Reframing hope: meaning‐centered care for patients near the end of life. J Palliat Med 2003; 6: 979 – 988. https://doi.org/10.1089/109662103322654901
dc.identifier.citedreferenceBrady MJ, Peterman AH, Fitchett G, et al. A case for including spirituality in quality of life measurement in oncology. Psycho‐Oncology 1999; 8: 417 – 428.
dc.identifier.citedreferenceBreitbart W, Pessin H, Rosenfeld B, et al. Individual meaning‐centered psychotherapy for the treatment of psychological and existential distress: a randomized controlled trial in patients with advanced cancer. Cancer 2018; 124: 3231 – 3239. Available from http://www.ncbi.nlm.nih.gov/pubmed/29757459
dc.identifier.citedreferenceBreitbart W, Poppito S, Rosenfeld B, et al. Pilot randomized controlled trial of individual meaning‐centered psychotherapy for patients with advanced cancer. J Clin Oncol 2012; 30: 1304 – 1309.
dc.identifier.citedreferenceBreitbart W, Rosenfeld B, Gibson C, et al. Meaning‐centered group psychotherapy for patients with advanced cancer: a pilot randomized controlled trial. Psychooncology 2010; 19: 21 – 28. https://doi.org/10.1002/pon.1556
dc.identifier.citedreferenceRodin G, Lo C, Rydall A, et al. Managing Cancer and Living Meaningfully (CALM): a randomized controlled trial of a psychological intervention for patients with advanced cancer. J Clin Oncol 2018; 36: 2422 – 2432.
dc.identifier.citedreferenceChochinov HM, Hack T, Hassard T, et al. Dignity therapy: a novel psychotherapeutic intervention for patients near the end of life. J Clin Oncol 2005; 23: 5520 – 5525.
dc.identifier.citedreferenceReady RE, Boileau NR, Barton SK, et al. Positive affect and well‐being in Huntington’s disease moderates the association between functional impairment and HRQOL outcomes. J Huntington’s Dis 2019; 8: 221 – 232. https://doi.org/10.3233/JHD‐180341
dc.identifier.citedreferenceSalsman JM, Victorson D, Choi SW, et al. Development and validation of the positive affect and well‐being scale for the neurology quality of life (Neuro‐QOL) measurement system. Qual Life Res 2013; 22: 2569 – 2580.
dc.identifier.citedreferenceJackson WT, Novack TA, Dowler RN. Effective serial measurement of cognitive orientation in rehabilitation: the orientation log. Arch Phys Med Rehabil 1998; 79: 718 – 721.
dc.identifier.citedreferenceHanauer DA, Mei Q, Law J, et al. Supporting information retrieval from electronic health records: a report of University of Michigan’s nine‐year experience in developing and using the Electronic Medical Record Search Engine (EMERSE). J Biomed Inform 2015; 55: 290 – 300. https://doi.org/10.1016/j.jbi.2015.05.003
dc.identifier.citedreferencePaulsen JS, Langbehn DR, Stout JC, et al. Detection of Huntington’s disease decades before diagnosis: the Predict‐HD study. J Neurol Neurosurg Psychiatry 2008; 79: 874 – 880.
dc.identifier.citedreferenceKieburtz K, Penney JB, Corno P, et al. Unified Huntington’s disease rating scale: reliability and consistency. Neurology 2001; 11: 136 – 142.
dc.identifier.citedreferenceShoulson I, Kurlan R, Rubin AJ, et al. Assessment of functional capacity in neurodegenerative movement disorders: Huntington’s disease as a prototype. Quantif Neurol deficit Bost Butterworths 1989; 271 – 283.
dc.identifier.citedreferenceHeaton RK. Revised comprehensive norms for an expanded Halstead‐Reitan Battery: demographically adjusted neuropsychological norms for African American and Caucasian adults, professional manual. Psychol Assess Resour 2004.
dc.working.doiNOen
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.